Hemolysis during salicylazosulfapyridine therapy.

Area of Science:

• Pharmacology
• Gastroenterology
• Clinical Medicine

Background:

• Salicylazosulfapyridine (SASP) is a common treatment for ulcerative colitis and Crohn's disease.
• Hemolysis is a potential adverse effect of SASP therapy.
• The relationship between SASP metabolite levels and hemolysis requires further investigation.

Purpose of the Study:

• To investigate the incidence of hemolysis in patients with inflammatory bowel disease receiving SASP.
• To examine the correlation between serum levels of SASP, free sulfapyridine (SP), and acetyl sulfapyridine (ac-SP) and the occurrence of hemolysis.
• To assess the role of acetylator phenotype in SASP-induced hemolysis.

Main Methods:

• Studied 36 unselected patients with ulcerative colitis or Crohn's disease on daily SASP (4.5-6 gm).
• Measured serum levels of SASP, free SP, and ac-SP.
• Assessed for hemolysis and determined acetylator phenotype.

Main Results:

• Hemolysis was present in 19 out of 36 patients.
• Significantly higher serum levels of free SP were observed in patients with hemolysis (P < 0.001).
• All patients with serum SP > 37 microgram/ml had hemolysis; 18 of 19 patients with hemolysis were slow acetylators.

Conclusions:

• Elevated free sulfapyridine serum levels are strongly associated with hemolysis in patients treated with salicylazosulfapyridine.
• The slow acetylator phenotype is linked to an increased risk of developing hemolysis during SASP therapy.
• Monitoring free SP levels and acetylator status may help predict and prevent SASP-induced hemolysis.